Clinical Trial Evaluating Moxibustion for Cold-Syndrome Allergic Rhinitis
ClinicalTrials.gov Studies
Summary
NIH's ClinicalTrials.gov has registered a new interventional study (NCT07537439) evaluating the adjunctive effects of mild moxibustion combined with fluticasone propionate (100 mcg) for treating cold-syndrome allergic rhinitis. The randomized trial will assess outcomes including symptom relief, quality of life, and work productivity in patients with IgE-mediated allergic rhinitis. Estimated study completion date is April 17, 2026.
What changed
A new clinical trial has been registered on ClinicalTrials.gov (NCT07537439) studying mild moxibustion as an adjunctive treatment for cold-syndrome allergic rhinitis. The two-arm randomized trial will compare moxibustion combined with fluticasone propionate 100 mcg against standard pharmacological treatment alone. The study addresses patients with IgE-mediated allergic rhinitis who experience symptoms including nasal obstruction, rhinorrhea, sneezing, and itching despite existing therapies.
For sponsors and clinical investigators, this registration represents standard ClinicalTrials.gov posting requirements under FDAAA 801 for applicable clinical trials. Healthcare providers and patients may note this as an emerging complementary therapy research avenue, though the study is still recruiting with an estimated completion date of April 2026. The registration provides transparency on trial design, interventions, and anticipated endpoints for stakeholders monitoring allergic rhinitis treatment innovations.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Evaluation of the Adjunctive Effects of Moxibustion in the Treatment of Cold-Syndrome Allergic Rhinitis
N/A NCT07537439 Kind: NA Apr 17, 2026
Abstract
Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa characterized by one or more of the following symptoms: nasal obstruction, rhinorrhea, sneezing, and nasal itching. It is an IgE-mediated immune disorder that typically occurs after exposure to allergens such as pollen, house dust mites, and animal dander. The reported prevalence of rhinitis in adults ranges widely from 1% to over 60%, largely depending on diagnostic definitions and geographic regions. Allergic rhinitis is estimated to affect approximately 10% to 30% of the global population and imposes a substantial burden on sleep quality, quality of life, cognitive function, and work productivity.
Due to its chronic course, frequent recurrence, and complex pathophysiology, allergic rhinitis not only adversely affects patients' physical and mental health and overall quality of life but also results in significant socioeconomic burden. Current standard management strategies include allergen avoidance and pharmacological treatments such as oral and intranasal antihistamines, leukotriene receptor antagonists, and intranasal glucocorticoids. However, despite stepwise treatment approaches, a considerable proportion of patients continue to experience persistent symptoms and impaired quality of life, and may suffer from medication-related adverse effects, including drowsiness, dryness of the nasal or ocular mucosa, and nasal irritation.
Allergen-specific immunotherapy is currently regarded as the only disea...
Conditions: Allergic Rhinitis (AR)
Interventions: Mild moxibustion, Fluticasone propionate 100 mcg
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.